Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. They aim to discover and develop breakthrough treatments that harness the body's immune system to fight cancer. Arcus Biosciences utilizes a combination of small molecules and antibodies to target specific immune checkpoints and pathways involved in tumor growth and immune evasion. Their goal is to improve outcomes for patients with various types of cancer and provide new treatment options where existing therapies have limitations.

The stock of Arcus Biosciences, ticker symbol RCUS, is currently experiencing a messy trend. A messy trend refers to a period of price action that lacks a clear and consistent direction. The stock price may exhibit erratic movements, frequent fluctuations, and a lack of well-defined patterns. This type of trend can make it challenging for traders and investors to identify clear entry or exit points. 

It is important to exercise caution and closely monitor the price action for any signs of a potential trend development or consolidation before considering any significant trading or investment decisions.